CTLA-4

Scientific explanation

CTLA-4 competes with CD28 for B7 ligands, restraining priming of T cells mainly in lymphoid tissues and Tregs.

Cancers where relevant

MSI-high colorectal cancer Hodgkin lymphoma Melanoma

Compounds that intersect this pathway

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.